Drain placement after thyroidectomy does not reduce complication rates and may increase infection risk and hospital length of stay, although their use may still be appropriate in high-risk cases.


Drain placement after thyroidectomy does not reduce complication rates and may increase infection risk and hospital length of stay, although their use may still be appropriate in high-risk cases.

Given the significant potential benefit with limited risk of complications, TCAL should be performed concurrently with TORS to decrease the risk of severe post-operative bleeding. Future studies should examine the optimal TCAL approach (selective ECA branches vs. total ligation of the ECA).

Temporal bone ORN is a rare but serious complication of head and neck cancer treatment. Medical management, including topical antimicrobials, debridement, PENTO protocol, HBO therapy, and pain relief, can be effective for localized cases. Surgical intervention is recommended for diffuse disease, severe pain, uncontrolled infections, cholesteatomas, and patients over 60. More research and randomized control trials are needed to determine the best treatment approaches.

Over the past few decades, a transition toward culture-directed antibiotics has shifted the treatment paradigm of SBO toward primary medical management, with mortality rates now decreasing to 10-20% compared to 50% initially.

Medullary thyroid carcinoma (MTC) comprises less than 5% of thyroid cancers but is responsible for more than 10% of deaths related to thyroid cancer.
Antithrombotic management is a key component of surgical optimization, as it necessitates balancing the risk of a peri-operative thrombotic event with the risk of bleeding.

The use of p16 as a surrogate marker for HPV has gained traction, but is it sufficient as a surrogate for HPV-related squamous cell carcinoma?

Most current literature suggests that cefazolin is safe for surgical prophylaxis in patients with penicillin allergy.
Multimodal pre-habilitation and rehabilitation have been an important topics in the literature, aiming to combat modifiable patient factors like sarcopenia, malnutrition, and psychological status.

Resectable stage IVA/IVB tumors should be treated with surgery followed by chemoradiation, with consideration for dabrafenib/trametinib biotherapy for BRAFV600E-mutated tumors.